Advancing B7-H3 Targeted Therapy for Relapsed Extensive-Stage Small Cell Lung Cancer
The FDA’s Priority Review of ifinatamab deruxtecan was recently announced, a potential first-in-class B7-H3 targeted therapy. The Biologics License Application for ifinatamab deruxtecan (I-DXd), a B7-H3 directed DXd antibody drug conjugate (ADC), has been accepted with a Prescription Drug User Fee Act (PDUFA) target action date of October 10, 2026. If approved, it would become the first B7-H3 directed ADC for adult patients with extensive-stage small cell lung cancer (ES-SCLC) who progressed after platinum-based chemotherapy.
Strong Antitumor Activity in Heavily Pretreated Patients
The most impactful finding from the IDeate-Lung01 Phase 2 trial is the demonstration of clinically meaningful objective response rates with ifinatamab deruxtecan in a population with very limited treatment options. Data presented at the 2025 World Conference on Lung Cancer and published in the Journal of Clinical Oncology showed robust efficacy at the 12 mg/kg dose, supported by results from the IDeate-PanTumor01 Phase 1/2 trial. Secondary endpoints including duration of response, progression-free survival, and intracranial objective response rate further underscore the potential of B7-H3 targeted therapy, especially given small cell lung cancer’s high propensity for brain metastases.
Global Trial Design Built for Real-World Relevance
IDeate-Lung01 is a global, multicenter, randomized, open-label Phase 2 trial that enrolled 187 patients with ES-SCLC across Asia, Europe, and North America. Participants had received at least one prior line of platinum-based chemotherapy and no more than three total lines of therapy. The trial permitted patients with asymptomatic brain metastases, whether treated or untreated. Part 1 randomized patients to 8 mg/kg or 12 mg/kg of ifinatamab deruxtecan every three weeks to optimize dosing, while Part 2 evaluated the selected 12 mg/kg dose. The primary endpoint was objective response rate by blinded independent central review per RECIST v1.1, with key secondary endpoints including duration of response, progression-free survival, overall survival, and safety.
HEOR and Market Access Implications of First-in-Class B7-H3 ADCs
The potential approval of this B7-H3 targeted therapy would mark a significant milestone for approximately 27,000 U.S. patients diagnosed with ES-SCLC each year. From a health economics perspective, a therapy with demonstrated intracranial activity could reduce neurologic complications and associated healthcare costs in a disease notorious for rapid progression and poor long-term survival. The FDA’s use of Priority Review, Real-Time Oncology Review, Project Orbis, and Breakthrough Therapy Designation reflects strong regulatory confidence and may accelerate global access. Payers will likely seek mature overall survival data from the ongoing Phase 3 IDeate-Lung02 trial to support reimbursement. Successful market entry could also set new benchmarks for value-based pricing of antibody drug conjugates in aggressive thoracic cancers.
